الفهرس Only 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
The cause of chronic myeloid leukemia is a constitutively active BCR-ABL tyrosine kinase enzyme. Imatinib,Dasatinib and Nilotinib inhibit this kinase .We analyzed the results of response in patients of ph+ve CML who attended Kasr El Aini center of radiation oncology during the period Jan.2009 to Jan 2014 .We analyzed hematologic and molecular response, together with progression free survival and adverse events.Imatinib induced a hematological response in almost all cases, but its molecular response was less. Dasatinib and Nilotinib were used as a second line after Imatinib failure, suboptimal response, or intolerable adverse effects